[1] |
YANG Sheng, WANG Deguo.
Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
|
[2] |
FAN Jianfeng,FANG Yi,ZHENG Chunhua.
Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 810-814.
|
[3] |
WEI Zihan,LI Dongbo,YUAN Zheng,LU Ying, YANG Guojie.
Clinical trial of sacubitril/valsartan in the treatment of Pulmonary hypertension (PH) due to left heart disease (LHD)
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 57-62.
|
[4] |
ZHAO Yanyun, WU Xiaoyan, WANG Guomin, FENG Yulin, DONG Feixia.
Experimental study of benazepril intervene Wnt signaling inhibits renal fibrosis in UUO rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1332-1339.
|
[5] |
LI Xiao-yan, ZHANG Ping, TAO Ling, LIU Yu-xing.
Effect of candesartan on HOMA-IR and serum adiponectin of spontaneously hypertensive rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(11): 1201-1204.
|
[6] |
YANG Yan-lang1,2, ZOU He-qun1, ZHANG Dao-you2, WANG Yu-wei2, LI Fan-xia2, GAO Chao-qing2, XU Hai-hong2, CHENG Xiao-mei2.
Renal tubular protection effect of combining benazepril and spironolactone in adriamycin-induced nephritic rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 381-386.
|
[7] |
CHEN Hua, YING Wei-xing, LI Rong-zhou.
Combined treatment of vitamin K2 and benazepril induces apoptosis and inhibits angiogenesis on gastric cancer in vitro experiments
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(6): 621-626.
|
[8] |
LI Ling, TAN Zhi-rong, CHEN Yao, ZHOU Gan, GUO Dong, YAN Jin, YANG Guo-ping, OUYANG Dong-sheng.
A rapid and sensitive LC-MS/MS method for determination of valsartan in human plasma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(7): 809-813.
|
[9] |
WU Xiao-dong, ZHANG Dao-you, CUI Ming-chun, YANG Li-cai, YANG Yan-lang, ZHU Xin-jian.
Influence of valsartan and fluvastatin on hepatocyte growth factor in adriamycin-induced nephrotic rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(3): 305-309.
|
[10] |
WANG Xin, YANG Yu-wen, WANG An-cai, KONG Xiang-quan.
Effects of valsartan on BKCa of hypoxic pulmonary hypertensive rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(9): 1032-1035.
|
[11] |
YANG Yan-lang, ZHANG Dao-you, WANG Xiang-ming, CUI Ming-chun, WU Xiao-dong.
Renoprotective effect and mechanisms of benazepril and pentifylline on adriamycin nephropathy rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(7): 736-740.
|
[12] |
CAO Dong-ping, PENG Ying-xin, YAO Wen-jing, RONG Chun-li, YU Wei, QIAO Shu-zhang.
Effects of valsartan-hydrochlorothiazide combination on early renal damage of the patients with essential hypertension
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(5): 567-571.
|
[13] |
FAN Jian-feng, TANG Sheng-xing, WAN Jun, ZHU Wei-ping, LI Bi-long, ZHU Zheng-cai.
Variations of pregnancy-associated plasma protein-A and C-reactive protein in essential hypertension patients with left ventricular hypertrophy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(2): 203-206.
|
[14] |
YANG Yu-wen, WANG De-guo, KONG Xiang-quan, XU Chen-hua.
Effects of valsartan on nuclear factor-κB protein expression in the kidney of spontaneously hypertensive rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(9): 1002-1004.
|
[15] |
XU Hai-hong, YANG Li-cai, YANG Yan-lang, ZHANG Dao-you.
Valsartan decrease expression of endothelin-1 in myocardium of rats with chronic renal failure
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(6): 639-643.
|